|
Transfusion Support of Patients with Myelodysplastic Syndromes |
Dec 2023 |
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
|
Traipsing Through Muddy Waters: A Critical Review of the Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes |
Apr 2021 |
Hematology/oncology clinics of North America |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
|
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype |
Jul 2020 |
Blood |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. |
Jan 2019 |
Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Towards graft- versus-host disease-free alternative donor transplant platforms for patients with acquired aplastic anemia |
May 2025 |
Haematologica |
Aplastic Anemia, Graft Versus Host Disease (GVHD) |
|
Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes |
Jun 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS) |
May 2024 |
HemaSphere |
Myelodysplastic Syndromes (MDS) |
|
To Target the Untargetable: Elucidation of Synergy of APR-246 and Azacitidine in TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia |
Jun 2020 |
Haematologica |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes |
Apr 2023 |
Haematologica |
Myelodysplastic Syndromes (MDS) |
|
Thrombosis in Paroxysmal Nocturnal Hemoglobinuria (PNH): From Pathogenesis to Treatment |
Nov 2024 |
International Journal of Molecular Sciences |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
